Yazılar

German TikTok Users Show Greater Sympathy for China, Russia, Poll Reveals

/in /tarafından

Germans who rely on TikTok for news are less critical of China and Russia and more skeptical of climate change and vaccine effectiveness compared to consumers of traditional media, according to a recent survey by Allensbach, commissioned by a foundation linked to Germany’s liberal Free Democrats.

The poll highlights that only 28.1% of TikTok users fully agreed that China is a dictatorship, compared to 57% of newspaper readers and 56.5% of public TV viewers. Similarly, just 13.6% of TikTok users supported Western backing for Ukraine in its war against Russia, a view shared by 40.2% of national newspaper readers.

The findings come amid U.S. debates on whether to enforce a ban on TikTok over national security concerns, adding weight to arguments that the Chinese-owned app spreads misinformation that could undermine democratic societies.

Key Findings:

  • Perception of China: TikTok users are less likely to view China as a dictatorship.
  • Views on Russia: Fewer TikTok users see Russia’s invasion of Ukraine as illegal or support Germany aiding Kyiv.
  • Skepticism on Vaccines and Climate Change: Only 69% of TikTok users under 29 agreed that vaccines saved millions of lives, compared to 71% of all under-29s.
  • Distrust in Media: TikTok users are more likely to distrust traditional Western media and to believe the German government spreads misinformation, while being less critical of disinformation from China and Russia.

These attitudes align with broader trends among younger Germans, who are TikTok’s core demographic and have shown increased support for the far-right Alternative for Germany (AfD) party in recent elections.

Disinformation Concerns

The survey also raises alarms about foreign actors, especially Russia, spreading disinformation via social media platforms to advance their agendas. Researchers cited parallels with Romania, where a pro-Russian outsider gained significant traction through social media campaigns in a presidential election later annulled.

Sabine Leutheusser-Schnarrenberger, deputy chair of the foundation behind the survey, emphasized TikTok’s influence, saying, “Young people are far more vulnerable to information, and TikTok plays a decisive role. We mustn’t allow Chinese and Russian misinformation to spread in our midst.”

TikTok’s parent company, ByteDance, has not commented on the survey.

 

One Major Challenge Facing Trump’s Chosen Health Leaders: Keeping Politics Separate from Science

/in /tarafından

When President-elect Donald Trump announced his picks for top health leadership roles, including Dr. Janette Nesheiwat for U.S. surgeon general, Dr. David Weldon for CDC director, and Dr. Marty Makary for FDA commissioner, reactions among public health experts were mixed. These leaders face scrutiny not just for their qualifications, but for how they’ll handle the inevitable conflict between political pressure and scientific integrity.

Reactions to the Appointments

Experts generally expressed approval of Nesheiwat and Makary, but many voiced concerns about Weldon, particularly due to his controversial past views on vaccine safety. As public health agencies like the CDC and FDA are crucial in shaping health policy, the independence of these leaders will be closely watched. A central issue is whether they will maintain a commitment to evidence-based science, despite political pressures, especially with figures like Robert F. Kennedy Jr. – an outspoken anti-vaccine advocate – leading the Department of Health and Human Services (HHS).

Challenges in Maintaining Scientific Integrity

Public health experts emphasized the difficulty these appointees will face in resisting external political influences. Brown University’s Dr. Ashish Jha warned that it could be “very hard to defy your boss,” referencing the challenges faced by the CDC and FDA leaders if they are pressured by someone with anti-science views like Kennedy.

Nesheiwat and Makary are seen as open-minded physicians, but experts fear that Weldon’s history of questioning vaccine safety could have a damaging influence on his leadership at the CDC. Dr. Jerome Adams, former surgeon general under Trump, raised concerns about Weldon’s previous efforts to separate vaccine safety from CDC oversight, calling it a “disastrous” move for public health if promoted again.

Vaccine Policy as a Key Issue

Vaccination policy, especially in light of the COVID-19 pandemic, remains one of the most pressing issues for U.S. health agencies. Experts like Dr. Peter Hotez of Texas Children’s Hospital and Dr. Jennifer Nuzzo of Brown University underscored that a health leader’s stance on vaccines is a crucial indicator of their ability to make scientifically sound decisions. For example, Weldon’s past support for anti-vaccine measures raises concerns that his leadership could lead to reduced vaccination rates, with severe consequences such as measles outbreaks.

Dr. Paul Offit, a leading vaccine expert, warned that the possible return of measles, a disease previously eradicated due to widespread vaccination, could be a direct consequence of appointing leaders who subscribe to or enable vaccine misinformation.

Public Health and Political Influence

While the CDC and FDA are typically independent of political influence, many experts worry that under Kennedy’s leadership at HHS, there will be unprecedented interference. This raises questions about whether these agencies will be able to focus on public health science rather than political considerations. Dr. Hotez remarked that ensuring science-driven policy remains at the forefront is vital to avoid unnecessary public health crises.

In response to concerns about Weldon’s views on vaccines, experts like Dr. Amesh Adalja from the Johns Hopkins Center for Health Security emphasized the dangers of elevating individuals with a history of promoting vaccine misinformation. If confirmed, experts fear that this could lead to the dismantling of trusted vaccine programs, reversing progress made in public health.

Uncertain Future for Makary and Nesheiwat

Makary and Nesheiwat remain somewhat enigmatic figures in the public health arena. While they have demonstrated solid medical knowledge, the concerns revolve around their ability to navigate the political environment, particularly in relation to vaccine policy. Experts like Dr. Offit hope that Makary will take a firm stance against the anti-vaccine rhetoric of figures like Kennedy, but his previous hesitations regarding vaccine-related issues leave some uncertainty.

Conclusion

The upcoming Senate confirmations for these key health roles will be crucial in determining whether politics or science will take precedence in U.S. public health policy. As experts express concern over the influence of political figures like Robert F. Kennedy Jr., the broader public health community is watching closely to see whether Trump’s nominees will maintain their independence or succumb to political pressures.

 

Merck Shares Fall 9% Despite Earnings Beat and Strong Demand for Key Drugs

/in /tarafından

Merck reported second-quarter revenue and adjusted earnings that exceeded Wall Street’s expectations, driven by strong sales from its blockbuster cancer drug Keytruda and other treatments in its oncology and vaccines portfolios, as well as a newly launched cardiovascular drug. Despite this, Merck’s shares fell by 9% due to lighter-than-expected sales of Gardasil, a vaccine for HPV, exacerbated by shipment issues in China.

Merck raised its full-year sales forecast to $63.4 billion to $64.4 billion, slightly up from its previous guidance of $63.1 billion to $64.3 billion. However, it lowered its adjusted profit guidance to a range of $7.94 to $8.04 per share, down from $8.53 to $8.65 per share, reflecting one-time charges for its acquisitions of Harpoon Therapeutics and EyeBio.

For the second quarter, Merck reported adjusted earnings per share of $2.28, surpassing the expected $2.15, and revenue of $16.11 billion, above the anticipated $15.84 billion. The company posted a net income of $5.46 billion, or $2.14 per share, compared to a net loss of $5.98 billion, or $2.35 per share, in the same period last year.

Keytruda recorded $7.27 billion in revenue, up 16% year-over-year, driven by higher uptake for earlier-stage cancers and strong demand for metastatic cancers. Gardasil sales increased by only 1% to $2.48 billion due to shipment timing issues in China. Winrevair, approved in March for treating a progressive lung condition, posted $70 million in revenue, while Capvaxive, a newly approved pneumococcal vaccine, is expected to drive future growth.

Merck’s pharmaceutical division saw a 7% increase in revenue to $14.41 billion. The company’s Type 2 diabetes treatment, Januvia, faced a 27% decline in sales to $629 million due to lower demand, prices, and generic competition. Sales of Merck’s Covid antiviral pill, Lagevrio, fell by 46% to $110 million but still exceeded expectations.

Merck’s animal health division reported $1.48 billion in sales, up 2% from the previous year, but slightly below analyst expectations. Despite strong overall performance, investor concerns about Gardasil sales and future challenges in the pharmaceutical landscape influenced the decline in Merck’s stock.